Literature DB >> 21597229

High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.

Junko Miyamoto Igaki1, Makoto Yamada, Yuji Yamazaki, Shinobu Koto, Masako Izawa, Daisuke Ariyasu, Eri Suzuki, Hisashi Hasegawa, Yukihiro Hasegawa.   

Abstract

X-linked hypophosphatemic rickets (XLH) is caused by inactivating mutations in the phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) gene. Deletion of Phex leads to increased serum fibroblast growth factor23 (FGF23) levels in mouse. The aim is to assure the clinical usefulness of FGF23 determination in the diagnosis of XLH. Participants were 21 patients with XLH having abnormalities in PHEX from 13 kindred (PtPHEX: 1 to 42 years old; 10 males, 11 females) and 55 healthy controls (1 month to 18 years old; 27 males, 28 females). Temporal changes in FGF23 were determined by a single oral phosphate administration in PtPHEX and an ad lib diet in controls. Reference ranges of intact FGF23 (iFGF23) for children were determined. iFGF23 level which distinguish between controls and PtPHEX were validated. Correlations between iFGF23 and the severity of XLH (gender, age of onset, bone deformity, The ratio of maximum rate of renal tubular reabsorption of phosphate to glomerular filtration rate (TmPO(4)/GFR), inorganic phosphate (IP), Alkaline Phosphatase (ALP), therapeutic dose) were investigated. Increasing tendency after phosphate administration and no general tendency after breakfast in iFGF23 were observed. Reference range (5(th) and 95(th) percentiles) of iFGF23 for children (12.9 and 51.2 pg/mL) was similar to that for adults. iFGF23 were above the reference range in 19 of 21 PtPHEX (40 to 4710 pg/mL). iFGF23 did not correlate with any index of severity of XLH. Relatively high iFGF23 despite hypophosphatemia is one of the clinical indicators to diagnose XLH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21597229     DOI: 10.1507/endocrj.k10e-257

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

Review 1.  Congenital Conditions of Hypophosphatemia Expressed in Adults.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-05-14       Impact factor: 4.333

Review 2.  The changing face of hypophosphatemic disorders in the FGF-23 era.

Authors:  Janet Y Lee; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

3.  X-linked hypophosphatemic rickets (PHEX mutation): A case report and literature review.

Authors:  Badi Alenazi; M A Maleque Molla; Abdullah Alshaya; Mahmoud Saleh
Journal:  Sudan J Paediatr       Date:  2017

Review 4.  Hypophosphatemic rickets due to perturbations in renal tubular function.

Authors:  Maria Goretti M G Penido; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2013-05-01       Impact factor: 3.714

5.  Mutation in Phex gene predisposes BALB/c-Phex(Hyp-Duk)/Y mice to otitis media.

Authors:  Fengchan Han; Heping Yu; Ping Li; Jiangping Zhang; Cong Tian; Hongbo Li; Qing Yin Zheng
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

6.  Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children.

Authors:  Vickie Braithwaite; Kerry S Jones; Shima Assar; Inez Schoenmakers; Ann Prentice
Journal:  Endocr Connect       Date:  2013-12-19       Impact factor: 3.335

7.  Ovarian cancer-related hypophosphatemic osteomalacia--a case report.

Authors:  Hung-An Lin; Shyang-Rong Shih; Yu-Ting Tseng; Chi-Hau Chen; Wei-Yih Chiu; Chih-Yao Hsu; Keh-Sung Tsai
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

8.  Hypophosphatemic rickets developed after treatment with etidronate disodium in a patient with generalized arterial calcification in infancy.

Authors:  Kentaro Miyai; Daisuke Ariyasu; Chikahiko Numakura; Kaori Yoneda; Hitoshi Nakazato; Yukihiro Hasegawa
Journal:  Bone Rep       Date:  2015-09-09

9.  Genetic analysis combined with 3D-printing assistant surgery in diagnosis and treatment for an X-linked hypophosphatemia patient.

Authors:  Jie-Yuan Jin; Li-Yang Zhang; Shuai Guo; Ke Tang; Lei Zeng; Rong Xiang; Jie-Yu Liang
Journal:  J Clin Lab Anal       Date:  2022-02-02       Impact factor: 2.352

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.